| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.073 | 0.01 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |